Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, Deplanque et al. (2016) explored doxycycline's role in preventing erlotinib-induced folliculitis in patients with non-small-cell lung cancer, highlighting skin toxicity as a common side effect that can affect patient adherence to treatment.

This article describes the extraction and characterization method for wedelolactone from Eclipta alba but presents no new clinical results.

This study found that Eclipta alba (L.) cultivated in France exhibited significant anti-inflammatory, antioxidant, and anti-collagenase activities, attributed mainly to compounds like wedelolactone and demethylwedelolactone, suggesting potential use as an anti-aging cosmetic ingredient.

This study reviewed evidence on eribulin's efficacy and safety for treating metastatic triple-negative breast cancer, highlighting variable survival outcomes and manageable safety profiles for both monotherapy and combination therapies.

This study evaluated the wedelolactone content and antimicrobial activity of Eclipta alba and Wedelia chinensis extracts, finding a potential relationship between the concentration of wedelolactone and their in vitro antimicrobial effects against several pathogenic bacteria and yeast.

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

In this study, ELE was found to protect against oxidative stress-induced testosterone reduction in TM3 Leydig cells by increasing testosterone synthesis and decreasing its conversion.

Equol may help with antiaging and skin health by boosting collagen and blocking certain hormones.

In this study, the combination of petroleum ether extracts from Jacquinia ruscifolia flowers and Thuja orientalis strobili demonstrated synergistic larvicidal effects against third-instar Culex quinquefasciatus larvae, achieving 100% mortality at 250 ppm with noted synergism particularly in a 1:2 ratio.

This case report describes an 11-year-old girl with eosinophilic pustular folliculitis that showed significant improvement with naproxen after being unresponsive to other treatments.

This study found that the ethanol extract of Eclipta alba significantly reduced gastric lesions and enhanced gastroprotective activity in ulcer-induced rats, suggesting potent antisecretory effects potentially linked to antioxidant properties.

This study suggests that ethyl acetate extract of Equisetum debile may be effective for functional food and nutraceutical use due to its strong 5α-reductase, IL-6 inhibition, and lipid peroxidation activities without cytotoxic effects.

The UK High Court revoked Lundbeck's patent for Escitalopram, and second medical use claims based on dosage were not considered novel.

This study found that the monophasic oral contraceptive ethinylestradiol/chlormadinone acetate was more effective in treating mild to moderate papulopustular acne in women than ethinylestradiol/levonorgestrel.

In this study, researchers identified several active metabolites in Eclipta alba, demonstrated strong interaction with Alzheimer's disease proteins, and found that 28 days of treatment improved memory without significant toxicity in rats, suggesting potential pathways for treating Alzheimer's.

This study reports that novel hexahydrobenzoquinolin compounds fully inhibited 5α-reductase activity in human genital skin fibroblasts, suggesting their potential for treating conditions like benign prostatic hyperplasia and male pattern baldness.

This book chapter reviews the taxonomy, traditional uses, pharmacological effects, and safety of Eclipta prostrata, emphasizing its potential therapeutic applications, but it reports no new clinical results.

In this reported case, a 30-year-old man with a long history of alopecia universalis experienced limited regrowth of eyebrows and eyelashes after six months of deuruxolitinib, despite unchanged scalp hair, suggesting site-specific potential for hair regrowth in challenging cases.

This study characterized Eclipta alba for use in a capillary product for alopecia, confirming its suitable physico-chemical properties and pharmacological constituents, including wedelolactone for hair growth.

This study found that methanolic extract of Eclipta alba leaves exhibited strong antibacterial effects against certain pathogens including methicillin-resistant Staphylococcus aureus, but it showed no activity against Mycobacterium tuberculosis, including drug-resistant strains.

In this study, EFH-SLM cream demonstrated greater efficiency in reducing hair density compared to plain EFH cream in Swiss albino female mice, with significantly less skin irritation and inflammation observed, suggesting improved permeability and effectiveness of EFH when using the new cream formulation.

This systematic review of three randomized controlled trials found that topical eflornithine is an effective adjunctive therapy for reducing unwanted facial hair in women with hirsutism, with benefits lasting at least six months, although efficacy may diminish over time.

This study reported that eflornithine cream, when used with laser hair removal, leads to faster reduction of unwanted facial hair in women and is similarly safe compared to the cream alone.

This study reported that dupilumab successfully induced remission of chronic, disseminated eczema herpeticum in a six-year-old girl with DOCK8-deficiency hyper-IgE syndrome, achieving complete resolution of herpetic lesions and significant skin, hair, and nail improvement within three months.

This article reviews the prescription-only cream eflornithine for managing facial hirsutism in women and reports no new clinical results; the authors evaluate its potential role in treatment.

New therapy helps treat hair loss.

This study found that eribulin-based chemotherapy resulted in longer median progression-free and overall survival, with fewer side effects, for advanced triple-negative breast cancer patients compared to other chemotherapy options.

This study evaluated the antimicrobial activity of a newly synthesized fluoroquinolone against Staphylococcus, Streptococcus, and Escherichia coli strains. The researchers compared results from the microdilution technique and agar disk diffusion method to EUCAST's recommended breakpoint values, building on promising in silico molecular docking tests.